Pandemic 2020

Status
Not open for further replies.

CunningCanuk

Well-Known Member
If people are concerned about masks, a free market approach can address that.

Those people who prefer to run their business as "mask required" and those people who want to run their business as "no mask required" should be allowed to. It should always be the property / business owner who sets the rules of conduct. I mean if people want to wear a mask to protect them from something they have a far less than 1% chance of dying from (if it is even real) it's not my business to stop them.

Some people just can't stop forcibly minding others business for them, can they ?
At a boy, Bob. Don’t let science or common sense sway you.
 

schuylaar

Well-Known Member
In Wednesday's case, the fivesome on the right wing had written that the New York restrictions "single out houses of worship for especially harsh treatment," in contrast to the Trump's travel ban, which the court two years ago had deemed "neutral."

Sotomayor noted that the Roman Catholic Diocese had argued that certain statements made by Cuomo reinforced its arguments that he had impermissibly targeted religious activity. Cuomo had rejected that characterization, as did Sotomayor as she said the court should not apply the toughest constitutional scrutiny to the New York occupancy limits.

"Just a few Terms ago, this Court declined to apply heightened scrutiny to a Presidential Proclamation limiting immigration from Muslim-majority countries, even though President Trump had described the Proclamation as a 'Muslim Ban,' originally conceived of as a 'total and complete shutdown of Muslims entering the United States until our country's representatives can figure out what is going on.
'
Concluded Sotomayor: "If the President's statements did not show 'that the challenged restrictions violate the 'minimum requirement of neutrality' to religion, it is hard to see how Governor Cuomo's do."

 

Dr.Amber Trichome

Well-Known Member
I've been watching the spike upward and it's like nothing we've seen.
It is indeed. I just saw today in OK 6,300 new positives . That’s a huge increase and Tulsa hospitals have moved to Tier 3 .
the article reported the anticipated wait for this new drug to be a game changer, so a bit of hopeful help .

“For those who are going to their primary care doctors or emergency rooms and end up testing positive for COVID-19 but aren’t sick enough to be hospitalized, Forrest said a new drug is “a game changer.” The drug, Bamlamivimab (bam-luh-MIH-VIH-mahb), which recently was given FDA emergency use authorization, will go from research use to general use Wednesday at Ascension St. John.

Because the drug can can cut the risk of having to later be hospitalized for COVID-19 by 75%, he said, “The more all of us in health care can get this into people who meet the criteria, we’re flattening the curve that way.”
 

DIY-HP-LED

Well-Known Member
I guess we know why Trump never seized all the vaccine for American use only. Moderna`s vaccine is made in Germany and the latest Oxford one made in the UK, looks like we are all in this together. America is first, because America has the biggest problem and initial distribution is based on need, we in Canada will wait until after the new year, but people are dying here too. Caring more about your rights than responsibilities to others has consequences that extend beyond America, we are all in this together.
-----------------------------------------------------------------------------------------------------------------------------------------

First doses of Pfizer coronavirus vaccine has flown to US from Belgium: report

The first doses of Pfizer's coronavirus vaccine candidate have been flown over to the U.S. from Belgium, a source familiar with United Airlines' COVID Vaccine Readiness Task Team planning confirmed to NBC on Saturday.

On Friday, the Wall Street Journal reported that United commenced chartering flights to send doses of the vaccine to the United States. In a statement to The Hill on Friday, the Federal Aviation Administration (FAA) also confirmed that it was "supporting the first mass air shipment of a vaccine."
A source told the network the FAA is allowing United to carry 15,000 pounds of dry ice per flight, which is five times over the permitted limit.

Pfizer's vaccine must be kept at below-freezing temperatures to maintain efficacy of the dosages.

United would not confirm details of the flight to The Hill but said it would "support a vaccine distribution effort on a global scale," noting its shipment run is through the United Cargo division of the airline.

Pfizer's vaccine candidate is developed in partnership with the German biotechnology company BioNTech, and last week, Pfizer applied for emergency use authorization (EUA) with the Food and Drug Administration (FDA). The vaccine will be distributed once it is approved.

According to a Financial Times Saturday report, the United Kingdom is slated to approve Pfizer's vaccine as early as next week.
 

Dr.Amber Trichome

Well-Known Member
I guess we know why Trump never seized all the vaccine for American use only. Moderna`s vaccine is made in Germany and the latest Oxford one made in the UK, looks like we are all in this together. America is first, because America has the biggest problem and initial distribution is based on need, we in Canada will wait until after the new year, but people are dying here too. Caring more about your rights than responsibilities to others has consequences that extend beyond America, we are all in this together.
-----------------------------------------------------------------------------------------------------------------------------------------

First doses of Pfizer coronavirus vaccine has flown to US from Belgium: report

The first doses of Pfizer's coronavirus vaccine candidate have been flown over to the U.S. from Belgium, a source familiar with United Airlines' COVID Vaccine Readiness Task Team planning confirmed to NBC on Saturday.

On Friday, the Wall Street Journal reported that United commenced chartering flights to send doses of the vaccine to the United States. In a statement to The Hill on Friday, the Federal Aviation Administration (FAA) also confirmed that it was "supporting the first mass air shipment of a vaccine."
A source told the network the FAA is allowing United to carry 15,000 pounds of dry ice per flight, which is five times over the permitted limit.

Pfizer's vaccine must be kept at below-freezing temperatures to maintain efficacy of the dosages.

United would not confirm details of the flight to The Hill but said it would "support a vaccine distribution effort on a global scale," noting its shipment run is through the United Cargo division of the airline.

Pfizer's vaccine candidate is developed in partnership with the German biotechnology company BioNTech, and last week, Pfizer applied for emergency use authorization (EUA) with the Food and Drug Administration (FDA). The vaccine will be distributed once it is approved.

According to a Financial Times Saturday report, the United Kingdom is slated to approve Pfizer's vaccine as early as next week.
I hope the plane doesn’t crash. I want one of them doses.
 

DIY-HP-LED

Well-Known Member
I hope the plane doesn’t crash. I want one of them doses.
With the shit storm American healthcare workers are about to face, I sure as shit hope so, the PPE situation in America is dire, we've been working the problem here for many months and are making home grown as well as importing. Healthcare workers will be front of the vaccine line, if the system goes down the mortality rate goes through the fucking roof. Healthcare workers are not the front line, that's our job, they are the last line of defense and that line is thin and breaking, Merry Christmas.>:(
 

DIY-HP-LED

Well-Known Member

The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Bamlanivimab for the Treatment of COVID-19
Last Updated: November 18, 2020

Bamlanivimab (also known as LY-CoV555 and LY3819253) is a neutralizing monoclonal antibody that targets the receptor-binding domain of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because this drug may block SARS-CoV-2 entry into host cells, it is being evaluated for the treatment of COVID-19.

On November 9, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to make bamlanivimab available for the treatment of nonhospitalized patients with mild to moderate COVID-19 who are at high risk for progressing to severe disease and/or hospitalization (see the specific EUA criteria for its use below).1 The issuance of an EUA does not constitute FDA approval of a product. The COVID-19 Treatment Guidelines Panel (the Panel) reviewed the available evidence from the published data on bamlanivimab for the treatment for COVID-19 and the FDA fact sheet that supported the EUA.

Based on the available evidence, the Panel has determined the following:

  • At this time, there are insufficient data to recommend either for or against the use of bamlanivimab for the treatment of outpatients with mild to moderate COVID-19.
  • Bamlanivimab should not be considered the standard of care for the treatment of patients with COVID-19.
  • An interim analysis of the BLAZE-1 study, a Phase 2, randomized, placebo-controlled trial, suggested a potential clinical benefit of bamlanivimab for outpatients with mild to moderate COVID-19. However, the relatively small number of participants and the low number of hospitalizations or emergency department visits make it difficult to draw definitive conclusions about the clinical benefit of bamlanivimab.
  • More data are needed to assess the impact of bamlanivimab on the disease course of COVID-19 and to identify those people who are most likely to benefit from the drug. Health care providers are encouraged to discuss participation in bamlanivimab clinical trials with their patients.
  • Given the possibility of a limited supply of bamlanivimab, as well as challenges distributing and administering the drug, patients at highest risk for COVID-19 progression should be prioritized for use of the drug through the EUA. In addition, efforts should be made to ensure that communities most affected by COVID-19 have equitable access to bamlanivimab.
  • Bamlanivimab should not be withheld from a pregnant individual who has a condition that poses a high risk of progression to severe COVID-19, and the clinician thinks that the potential benefit of the drug outweighs potential risk (see the criteria for EUA use of bamlanivimab below).
  • Patients who are hospitalized for COVID-19 should not receive bamlanivimab outside of a clinical trial.
  • The Panel will continue to evaluate emerging clinical data on the use of bamlanivimab for the treatment of outpatients with mild to moderate COVID-19 and anticipates updating these recommendations as more information becomes available.
Clinical Trial Data
 

DIY-HP-LED

Well-Known Member

Lilly and the Government of Canada sign an agreement for the supply of bamlanivimab to treat COVID-19 in Canada

Bamlanivimab is a SARS-CoV-2-neutralizing antibody that emerged from the collaboration between Lilly and Vancouver-based AbCellera

TORONTO, Nov. 24, 2020 /CNW/ - Eli Lilly Canada announced today that Lilly and the Government of Canada have signed an agreement for the supply of bamlanivimab to Canada. Lilly will supply Canada with an initial quantity of 26,000 doses of bamlanivimab over the three-month period between December 2020 and February 2021, for US$32.5 million. Lilly is taking a data-driven approach to the worldwide allocation of bamlanivimab according to our guiding principles that prioritize countries according to their medical need. Additional doses will be supplied to Canada on a monthly basis according to the medical need in Canada and the availability of supply.

The Government of Canada will be working with provincial and territorial partners to equitably allocate supply, while recognizing the need for flexibility based on COVID-19 activity across the country.

Bamlanivimab received authorization for its use as a treatment of adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization on November 20, 2020 under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

"From the beginning of our collaboration with AbCellera in March, through the interim authorization for the use of bamlanivimab in November, to an agreement on supply just days later, Lilly is bringing the full force of our expertise to meeting the challenge of COVID-19 in Canada, and around the world," said Rhonda Pacheco, President and General Manager, Lilly Canada. "We're grateful to the Government of Canada for their collaboration in working to quickly make this medicine available for Canadians."

About bamlanivimab
Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

About BLAZE-1
BLAZE-1 (NCT04427501) is a randomized, double-blind, placebo-controlled Phase 2 study designed to assess the efficacy and safety of bamlanivimab alone or in combination with a second antibody for the treatment of symptomatic COVID-19 in the outpatient setting. To be eligible, patients were required to have mild or moderate symptoms of COVID-19 as well as a positive SARS-CoV-2 test based on a sample collected no more than three days prior to drug infusion.

The monotherapy arms of the trial enrolled mild to moderate recently diagnosed COVID-19 patients, studying three doses of bamlanivimab (700 mg, 2800 mg, and 7000 mg) versus placebo. The primary outcome measure for the completed arms of the BLAZE-1 trial was change from baseline to day 11 in SARS-CoV-2 viral load. Additional endpoints include the percentage of participants who experience COVID-related hospitalization, ER visit or death from baseline through day 29, as well as safety.

The study is ongoing with additional treatment arms. Across all treatment arms, the trial will enroll over 800 participants.

Data from the monotherapy arms of BLAZE-1 were published in the New England Journal of Medicine.
 

DIY-HP-LED

Well-Known Member
An Oregon mink farm has reported a Covid-19 outbreak

An Oregon mink farm has reported a Covid-19 outbreak

(CNN)An Oregon mink farm has reported an outbreak of coronavirus among mink and farmworkers.

Ten mink samples submitted all came back positive for coronavirus, the Oregon Department of Agriculture (ODA) said in a news release on Friday. The farm has been placed under quarantine, meaning "no animal or animal product can leave the farm until further notice," according to ODA.
 

Budley Doright

Well-Known Member
the flip? they can re-sanitize and use for food again. winfvckingwin.

View attachment 4754974
It would seem the trickle down effect of trumps policies just keep trickling, like an enlarged prostate :(.
 

schuylaar

Well-Known Member
With the shit storm American healthcare workers are about to face, I sure as shit hope so, the PPE situation in America is dire, we've been working the problem here for many months and are making home grown as well as importing. Healthcare workers will be front of the vaccine line, if the system goes down the mortality rate goes through the fucking roof. Healthcare workers are not the front line, that's our job, they are the last line of defense and that line is thin and breaking, Merry Christmas.>:(
until there is 100% compliance we are on our own until vaccine. just walking the dog yesterday the maskless think because they're outside they're safe young and old alike- one wipe of the bare nose with the bare hand touch a door knob or call of duty dispenser? or the mouthbreather lady in the elevator where she just dropped liters into a covid tent in that lift- licking all the buttons was possible..i waited for the 2nd.

i leave not without a mask..if you look at me again cowboy hat it's getting flicked off with my new nordic walking pole.
 
Status
Not open for further replies.
Top